How the once-dominant cancer company has overhauled its strategy for long-term growth

The month also brought conversions to full approval for Retevmo and Sirturo

Plus: SpringWorks’ neurofibromatosis program headed for NDA and updates from Astellas, Propella, BMS, Merck, Nature’s Toolbox, Apollomics and Avistone

Plus: Deciphera gets lift from TGCT readout and updates from Hengrui, Merck KGaA, AnHeart, Nippon Kayaku, Novartis, GSK and more

Plus: GreenLight accepts a take-private offer, while Atea rejects one; and updates from Amylyx, Lexicon, Pfizer, BMS, Iovance and more  

Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon

In $4.1B deal, pharma pays more than double the biotech’s market valuation to gain targeted lung cancer therapy repotrectinib

BioCentury’s roundup of translational news

Blueprint receives $775M up front, diagnostic capabilities via licensing deal for RET inhibitor pralsetinib